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tient diagnostic codes forMS (ICD-9-CM 340) or one inpatient code during the index
period (1/1/2004-6/30/2008) were included. Continuous enrollment required 6 mos
pre-index and 12mos post-index. A sub-group of newly treated patients, defined as
MS patients free of DMT claims for 6 mos prior to initial MS diagnosis, were also
analyzed for frequencies of relapses. Using a claims-based definition, severe re-
lapses were defined as an inpatient hospitalizationwith a primary diagnosis of MS.
Moderate relapses were defined as an outpatient visit with a diagnosis of MS in
combination with a pharmacy or medical claim for a corticosteroid within 7 days
following the outpatient visit. Additional data collected included relapse-related
costs and length of inpatient stay. All variables were analyzed descriptively.
RESULTS: Among the 23,503 MS patients identified, mean age was 47 years and
18,027 (77%) were female. Overall, 1,479 (6.3%) patients had a relapse. 940 patients
(4.0%) had a severe relapse, with an average length of inpatient stay of 5.6 days.
Among, the sub group of newly treatedMSpatients (NTMS) (N 15,059), 1,059 (7.0%)
were classified as having a relapse, 710 (4.7%) were severe. Mean cost of relapse
[NTMS] was $12,558 [$11,485] for severe, and $1,561 [$1,844] for moderate.
CONCLUSIONS: This descriptive analysis provides an updated estimate of the fre-
quency and direct medical costs of both severe and moderate relapses among
multiple sclerosis patients. The ranges of health care services used to manage a
relapse reflect severity level. Further database analyses evaluating the impact of
disease modifying treatment on the rates and costs of relapses is warranted.
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OBJECTIVES: With inter- and intra-patient variation in cost and health resource
utilization, standard approaches to defining an episode of care (EOC) may perform
poorly. This study takes into account such variation and uses time-to-event anal-
ysis within an EOC framework to examine length and cost of care for vaso-occlu-
sive crisis (VOC) in sickle cell disease (SCD).METHODS: Florida Medicaid adminis-
trative data from 2001-2005 were used to examine EOCs. Enrollees under the age of
65 with 1 inpatient or 2 outpatient claims 30 days apart containing a primary
diagnosis of SCD (ICD-9 282.xx) and 6 months of continuous eligibility were in-
cluded in the study. Episodes began with the first VOC-related claim. Parametric
survival analysis was used to calculate episode length as the number of days by
which adjudicated payments returned to each patient’s pre-diagnosis average
charge. Episode costs were calculated as the difference between pre- and post-
diagnosis payments. EOCswere calculated by subgroups according to age (pediatric
and adult), gender, and presence of significant co-morbidity. RESULTS: Among
2,543 individuals included in the study, mean age was 14.4 years (standard devia-
tion [SD]11.9) and 48.2% were male. Mean episode length was 11.6 days (95%
confidence interval [CI]: 10.9-12.3). Pediatric patients had shorter episodes com-
pared to adults (10.5 versus 16.4 days, respectively), but there were no differences
by gender. The presence of acute chest syndrome secondary to VOC increased
episode length to 13.4 days. The incremental cost of VOC was $327 (95% CI: $310-
$343). Costs were slightly higher for males versus females and for adults versus
pediatric patients. CONCLUSIONS: Episode length as determined by parametric
survival analysiswas consistentwith the clinical presentation of VOC. Our analysis
suggests that cost may vary among patient groups with similar episode length.
Future work aims to quantify differences between standard and parameteric-
based EOC approaches.
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OBJECTIVES: Parkinson’s disease (PD) is a degenerative brain disorder of adult
onset that impairs motor function. As PD progresses, patients experience reduc-
tions in physical functioning and overall quality of life. Deep brain stimulation
(DBS) is an implantedmedical device that delivers electrical stimulation to specific
area(s) of the brain that control movement and muscle functioning. DBS has been
shown in clinical trials to significantly improve motor functioning, reduce disabil-
ity and improve the quality of life in patients and caregivers of PD patients. The
objective of this study is to compare the healthcare utilization and costs of PD
patients receivingDBS versusmedicallymanagement.METHODS: Patientswith PD
between 2006 and 2008 were identified the MarketScan Commercial Claims and
Encounters database. PD patients were segmented into medically managed pa-
tients and deep brain stimulation (DBS) patients. Medically managed PD patients
were required to be on at least one anti-parkinsonian medication. DBS patients
were identified using surgical procedure codes for lead implantation; an indexed
look-back period was used to ensure DBS patients were newly implanted. All pa-
tients were followed for one year. Annual healthcare utilization and per patient
healthcare costs were compared. RESULTS: We found that DBS patients had sig-
nificantly fewer inpatient hospitalizations (1.6 v. 2.4) and shorter lengths of stay
(2.8 v. 6.2) compared to medically managed PD patients (p 0.01). However, DBS
patients had significantly higher inpatient costs, resulting from the costs associ-
ated with DBS implantation. DBS patients had significantly lower annual pharma-
ceutical costs than PD patients ($7,105 v $11,735). The differences may be underes-
timated as DBS patients typically have more advanced PD than medically
managed. CONCLUSIONS: Our results demonstrate that medically managed PD
patients accrued significantly higher pharmaceutical costs and inpatient hospital-
ization stays compared to DBS patients. These results suggest DBS patients may
require fewer medications to manage PD symptoms.
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OBJECTIVES: This study aims to describe temporal trends and geographic discrep-
ancies on public pharmaceutical expenditures with multiple sclerosis (MS) treat-
ment in Brazil.METHODS: Longitudinal analysis of Brazilian MS pharmacy claims
as reported in the Brazilian Ambulatory Information System Database. Analyses
were based on aggregate data from the 27 Brazilian states, observed annually for
the period 2006–2009. The total MS-related expenditures were segmented by state,
drug (Glatiramer 20mg, Betainterferon 22mcg, Betainterferon 44mcg, Betainter-
feron 30 mcg, and Betainterferon 300mcg), and year. Per capita calculations were
also performed using Brazilian 2009 population. RESULTS:MS public expenditures
withMSdrugs had a significant rising from30,423,930BRL in 2006 to 214,405,349BRL
in 2009, a more than 7-fold increasing. Total investments in MS drugs totaled
629,917,685BRL. Federal funding transfers for the state of Roraima presented the
highest growth rate (1,497%) rising from 10,549BRL in 2006 to 157,973BRL in 2009.
São Paulo (41,384,039 inhabitants, 1/5 of Brazilian population) was responsible for
the higher absolute investment (13,130,526BRL and 88,948,997BRL in 2006 and 2009,
respectively) and the higher total expenditure for the period (259,591,564BRL, 1/3 of
national expenditures). The lowest spending was observed for states in the North
Region – Amapá had any MS claim in the 4-year period and Acre had the lowest
value (184,754BRL). Both states had similar projected 2009 population and are lo-
cated at regions with very similar characteristics (both ethnically and geographi-
cally). Betainterferon 44mcg represented the highest expenditures in 2009 and had
the highest annual cost per patient (54,288BRL). Conversely, Betainterferon 22mcg
was the only drug with decrement in the period, decreasing from 34,774,157BRL in
2007 to 32,304,159BRL in 2009. CONCLUSIONS:Our findings highlighted geographic
discrepancies within the Brazilian healthcare system in terms of MS treatment
funding even when demographic aspects were considered. Nevertheless a con-
stant increasing in public expenditures was observed across most states.
PND58
INPATIENT HEALTH RESOURCE UTILIZATION AMONG MULTIPLE SCLEROSIS
PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Takemoto MMS, Takemoto ML, Fernandes RA, Tolentino ACM, Santos PML, Duarte GGF,
Moretti AIP
ANOVA - Knowledge Translation, Rio de Janeiro, Brazil
OBJECTIVES: To describe inpatient resource use among multiple sclerosis (MS)
patients within the Brazilian public healthcare system (BPHS). METHODS: Inpa-
tient admissions were obtained from the Brazilian Hospital Information System
Database for the period 2006-2009. Records were included if an ICD-10 code G35
(MS) appeared as primary or secondary reason for hospitalization. The following
variables were collected: procedure code for the inpatient admission (relapseman-
agement versus other indications), mean length of stay, mean Intensive Care Unit
(ICU) days, in-hospital mortality, mean cost per hospitalization. Hospitalization
rates were calculated using the estimated MS population under treatment in the
BPHS (estimated from pharmacy claims). Relapse-related admissions were sepa-
rately analyzed. RESULTS: Annual hospitalizations due to MS were 2,142 in 2006,
2,268 in 2007, 1,648 in 2008, and 1,689 in 2009. The hospitalization rates among MS
patients attending BPHS facilities decreased from 0.60 in 2006 to 0.28 in 2009.
Among all admissions, 91.7%were relapse-related in 2006with similar proportions
in 2007 and 2008, and a slightly decrement in 2009 (88.0%). The in-hospital mortal-
ity rate is generally low, with the highest value in 2008 (3.09%) and the lowest in
2009 (1.6%). There were no differences between relapse-related and non-relapse-
related admissions in terms of in-hospital mortality. The mean length of stay was
8.9 days for all MS-related hospitalizations and 7.7 days for those to manage MS.
ICU claims were rare in this sample. In 2009, the observed average cost per hospi-
talization was 675 BRL and the total expenditure with MS inpatient admission was
1,140,418BRL (corresponding to 0.53% of pharmaceutical expenditures due to MS).
CONCLUSIONS:Relapses are responsible for over 90%of all inpatient admissions of
MS patients. Although higher health resource consumption is expected in the out-
patient setting, therapeutic strategies directed at reducing the incidence of re-
lapses can potentially lead to savings within the BPHS.
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OBJECTIVES: This study aimed to investigate the patterns ofmedication treatment
among patients with Multiple Sclerosis (MS) treated in the Brazilian Public Health-
care System (BPHS) and examine possible temporal and spatial trends in those
patterns. METHODS: The study was a longitudinal analysis of Brazilian MS phar-
macy claims as reported in the Brazilian Ambulatory Information SystemDatabase
for the period 2006-2009. Five different drugs currently recommended at BPHS MS
guidelines were included in the analysis (Glatiramer 20mg, Betainterferon 22mcg,
Betainterferon 44mcg, Betainterferon 30mcg, Betainterferon 300mcg) and the pro-
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